-
1 Comment
Quest PharmaTech Inc is currently in a long term downtrend where the price is trading 34.3% below its 200 day moving average.
From a valuation standpoint, the stock is 49.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 516.0.
Quest PharmaTech Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 336.0% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 93.8% to $-103K since the same quarter in the previous year.
Based on the above factors, Quest PharmaTech Inc gets an overall score of 3/5.
| ISIN | CA74836M1068 |
|---|---|
| Exchange | V |
| CurrencyCode | CAD |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 7M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.01 |
| Dividend Yield | None |
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for the potential cancer targets include pancreatic, colon, leukemia, ovarian, and breast cancer. It is also involved in the development of Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. The company is headquartered in Edmonton, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for QPT.V using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
